Business Context and Reporting Period
Company: Silence Therapeutics plc (SLN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Silence Therapeutics is a clinical-stage biotechnology company developing siRNA therapeutics using its proprietary mRNAi GOLD platform. The company focuses on cardiovascular disease, hematology, and rare diseases. It has no approved products and generates revenue solely from collaboration agreements and royalties.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $43.3 | $31.6 | $21.7 |
| Cost of Sales | $(11.8) | $(12.9) | $(13.5) |
| Gross Profit | $31.4 | $18.8 | $8.2 |
| Operating Loss | $(63.3) | $(64.4) | $(61.0) |
| Net Loss | $(45.3) | $(54.2) | $(50.3) |
| Cash & Equivalents (End of Period) | $121.3 | $68.8 | $66.3 |
| Short-term Investments | $26.0 | $0.0 | $0.0 |
| Total Liquidity (Cash + Investments) | $147.3 | $68.8 | $66.3 |
| Accumulated Deficit | $(474.0) | $(431.9) | $(380.1) |
Note: Financial statements were retrospectively converted from IFRS to U.S. GAAP effective January 1, 2025, due to the company's transition from a foreign private issuer to a U.S. domestic issuer.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 37% to $43.3 million in 2024, driven primarily by a $24.6 million cumulative catch-up recognition from the conclusion of the Hansoh collaboration. This was partially offset by a decrease in revenue from the Mallinckrodt collaboration, which concluded in March 2024.
- Net Loss Improvement: Net loss decreased to $45.3 million from $54.2 million in 2023, aided by a higher Benefit from R&D tax credit ($13.7 million vs. $11.9 million) and increased interest income ($4.5 million vs. $1.8 million).
- Operating Expenses: Research and Development (R&D) costs increased 19% to $67.9 million, reflecting increased clinical trial activity and contract manufacturing for proprietary programs. General and Administrative (G&A) expenses remained relatively flat at $26.9 million.
- Liquidity Position: Cash and short-term investments more than doubled to $147.3 million, bolstered by a $120 million private placement in February 2024 and $27.7 million raised under an Open Market Sale Agreement.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Capital Runway: Management believes existing cash and short-term investments ($147.3 million) are sufficient to fund operations into 2027.
- Product Pipeline:
- Divesiran (SLN124): Phase 2 SANRECO trial for Polycythemia Vera (PV) is underway; first subject dosed in December 2024. Positive interim Phase 1 data showed reduced phlebotomy requirements and lowered hematocrit levels.
- Zerlasiran (SLN360): Phase 2 data for cardiovascular disease (high Lp(a)) showed >80% reduction in Lp(a). Received positive regulatory feedback from FDA and EMA on Phase 3 design. Partnering discussions for Phase 3 development are ongoing.
- Collaborations: The Hansoh and Mallinckrodt collaborations concluded in 2024. The AstraZeneca collaboration remains active, with a Phase 1 trial ongoing for an undisclosed target.
Risks and Contingencies
- Profitability: The company has a history of net losses and expects to continue incurring significant losses for the foreseeable future. It has never generated revenue from product sales.
- Regulatory Approval: Success depends on obtaining regulatory approval for product candidates, which is uncertain and costly. Failure in clinical trials could halt development.
- Capital Requirements: Additional funding will be required to advance clinical trials and commercialize products. Failure to raise capital could force delays or discontinuation of programs.
- Compliance Transition: The transition to U.S. domestic issuer status (effective Jan 1, 2025) and loss of "emerging growth company" status will increase compliance costs and reporting requirements.
Investor Verification Checklist
- Collaboration Revenue Sustainability: Verify the impact of the concluded Hansoh and Mallinckrodt agreements on future revenue streams, as 2024 revenue was heavily influenced by catch-up accounting from these closures.
- Phase 3 Partnership for Zerlasiran: Confirm the status of global partnership discussions for Zerlasiran, as Phase 3 initiation is dependent on securing a partner.
- Cash Burn Rate: Monitor quarterly cash outflows from operating activities (which were $67.6 million in 2024) against the $147.3 million liquidity position to validate the 2027 runway estimate.
- Regulatory Milestones: Track enrollment progress in the Divesiran Phase 2 trial and the timeline for the Zerlasiran Phase 3 study start-up.
- Accounting Transition: Review future filings to ensure smooth adaptation to U.S. GAAP reporting standards following the retrospective conversion.